Stanford researchers have developed a novel therapeutic approach for neurodegenerative diseases by targeting endoplasmic reticulum (ER) stress in neurons using CHOP inhibitors, with significant potential for development into first-in-class neuroprotective drugs for neurodegene
Stanford scientists in Dr. Michael Lin's lab have established the use of B-cell reducing agents to improve an oncolytic virus (OV) therapy to rewire cancer signaling while limiting the production of antibodies against the virus in mouse studies.
Stanford researchers have developed a method of reducing pulmonary hypertension (PH) in mammals by targeting FHIT (Fragile Histidine Triad), a gene not previously linked to PH but consistently reduced in blood of patients with pulmonary arterial hypertension (PAH).
Researchers at Stanford and WashU developed cannabinoid receptor agonists with distribution mainly to peripheral tissues. Cannabinoid agonists are relevant for treatment of many indications, but current clinical use is limited by a variety of side effects.
Aging-associated mitochondrial dysfunction (mito-dysfunction) affects every cell system in our body. Mito-dysfunction includes reduced quality of mitochondrial DNA (mtDNA), irregular generation of reactive oxygen species, and membrane potential.
Stanford researchers have developed novel ENPP1 and ENPP3 inhibitors for cancer immunotherapy. ENPP1 inhibitors have previously been reported but ENPP3 is a newly discovered target.
Stanford scientists have developed an innovative 3D brain organoid culture system derived from adult neural stem cells to model neurodegenerative diseases like Alzheimer's and enable high-throughput drug screening.
Stanford scientists have developed a high throughput screening method to identify therapeutics known as translational activators to treat protein synthesis disorders and ribosomopathies.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Researchers at Stanford University and Washington University in St. Louis have discovered a novel molecular pathway for the treatment of opioid overdose.
Stanford researchers have discovered that tumors increase the risk of atherosclerosis by regulating expression of a specific gene that stimulates angiogenesis and intraplaque neovessel formation.
Stanford scientists have discovered a series of compounds that inhibit PTER and leads to weight loss. They found that inhibition of PTER, a key enzyme that regulates N-acetyltaurine metabolism, leads to N-acetyltaurine accumulation and a reduction in food intake.